Obesity, a growing global epidemic, is identified as a significant, modifiable risk factor for ovarian cancer, a deadly ...

Little is known about what causes ovarian cancer, and there is no way to detect it early yet. About 75% of the time when ...

Clinical application: Treatment in a mouse model with milciclib in combination with mirvetuximab significantly reduced tumor ...

Low-grade serous ovarian cancer (LGSC), accounts for just 5% to 10% of all epithelial ovarian cancers, but its distinct biology makes it especially challenging to treat. While the origin of this ...

Anixa Biosciences advances CAR T-cell therapy for recurrent ovarian cancer, targeting FSHR with promising safety and efficacy ...

To prevent ovarian cancers, fallopian tube removal is on an upsurge — and diagnostic manuals are finally catching up.

New combination therapy of relacorilant and nab-paclitaxel shows promise in extending survival for patients with ...

Little is known about what causes ovarian cancer, and there is no way to detect it early yet. About 75% of the time when ...

Blood-based circulating tumor DNA (ctDNA) testing has proven to be insufficient for detecting KRAS mutations in patients with ...

BerGenBio ASA (OSE: BGBIO) ("BerGenBio" or the "Company") and Oncoinvent ASA (OSE: ONCIN) ("Oncoinvent") announce that they have entered into a merger agreement (the "Agreement") to combine the two ...

Ovarian cancer in particular ... doesn't have great survival,” said one researcher. “Anything we can do to better understand ...